ImmunoGen in the NEWS
Immunogen (IMGN) - a developer of antibody-drug conjugates (ADCs) for cancer treatment , today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023.
Mark Enyedy, ImmunoGen’s President and Chief Executive Officer said, “Building on the momentum generated in the first half of 2023, we delivered a . . .